{"id":"W2999047517","doi":"10.1016/j.clgc.2019.12.019","title":"Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Janssen Pharmaceuticals; Bristol-Myers Squibb Canada; EMD Serono; Ipsen; Ferring Pharmaceuticals; Sanofi Genzyme; Merck Sharp and Dohme; Ferring; AstraZeneca; Invitae; Innocrin Pharmaceuticals; Astellas Pharma US; Flatiron Health; Dendreon Pharmaceuticals; Bayer Fund; Astellas Pharma Canada; F. Hoffmann-La Roche; Exelixis; Sanofi; Celgene; Novartis; Merck; Roche; American Association for Cancer Research; Amgen; Janssen Biotech; Johnson and Johnson; AcelRx Pharmaceuticals; Myovant Sciences; Pfizer; Bristol-Myers Squibb; Bayer; Calithera Biosciences; Constellation Energy Group","keywords":"Enzalutamide; Medicine; Cabazitaxel; Prostate cancer; Docetaxel; Prednisone; Abiraterone acetate; Internal medicine; Oncology; Confidence interval; Abiraterone; Clinical trial; Androgen deprivation therapy; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007834283,0.0002998337,0.0007498906,0.0001993691,0.00006334959,0.00004828914,0.0001233433,0.00007378314,0.00004474852],"category_scores_gemma":[0.0003214217,0.0001679513,0.00009414362,0.0007953088,0.0001859665,0.0001844612,0.00006270688,0.000695769,0.000003195585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003689203,"about_ca_system_score_gemma":0.000617012,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01016674,"about_ca_topic_score_gemma":0.01375939,"domain_scores_codex":[0.9963769,0.0008501863,0.001200674,0.0006321368,0.0004558575,0.0004841964],"domain_scores_gemma":[0.9971533,0.001896139,0.0002695431,0.0002669964,0.000155973,0.0002580275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009588482,0.001974009,0.9696417,0.0001268498,0.0002520695,0.001590931,0.002360158,0.0002163332,0.000002132972,0.000002627243,0.0001090533,0.01413565],"study_design_scores_gemma":[0.0172938,0.004070974,0.9736692,0.0002670999,0.0002072847,0.000002499803,0.001949652,0.000611821,0.000006676367,0.00001040738,0.001724972,0.0001855907],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9693987,0.0004869664,8.98575e-7,0.02754728,0.0000909753,0.002137263,0.0002301906,0.00001991904,0.00008775375],"genre_scores_gemma":[0.9854743,0.01035908,0.0003262871,0.002654239,0.0001458143,0.0006238457,0.0001923455,0.0000358964,0.0001882241],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02489304,"threshold_uncertainty_score":0.9964246,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.103478777189982,"score_gpt":0.4589470104597338,"score_spread":0.3554682332697519,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}